A Novel Multiplex HRM Assay to Detect Clopidogrel Resistance

作者：Zhang, Lichen; Ma, Xiaowei; You, Guoling; Zhang, Xiaoqing; Fu, Qihua^*

来源：Scientific Reports, 2017, 7(1): 16021.

DOI：10.1038/s41598-017-16310-8

• PERCUTANEOUS CORONARY INTERVENTION
• P-GLYCOPROTEIN
• GENETIC-POLYMORPHISM
• CYP2C19 GENOTYPE
• MELTING ANALYSIS
• IMPACT
• DISCRIMINATION
• RESPONSIVENESS
• PARAOXONASE-1
• VARIABILITY

Clopidogrel is an antiplatelet medicine used to prevent blood clots in patients who have had a heart attack, stroke, or other symptoms. Variability in the clinical response to clopidogrel treatment has been attributed to genetic factors. In particular, five SNPs of rs4244285, rs4986893, rs12248560, rs662 and rs1045642 have been associated with resistance to clopidogrel therapy in Chinese population. This work involves the development of a multiplex high-resolution melting (HRM) assay to genotype all five of these loci in 2 tubes. Amplicons corresponding to distinct SNPs in a common tube were designed with the aid of uMelt prediction software to have different melting temperatures Tm by addition of a GC-rich tail to the 5' end of the certain primers. Two kinds of commercial methods, Digital Fluorescence Molecular Hybridization (DFMH) and Sanger sequencing, were used as a control. Three hundred sixteen DFMH pretested samples from consecutive acute coronary syndrome patients were used for a blinded study of multiplex HRM. The sensitivity of HRM was 100% and the specificity was 99.93% reflecting detection of variants other than the known resistance SNPs. Multiplex HRM is an effective closed-tube, highly accurate, fast, and inexpensive method for genotyping the 5 clopidogrel resistance associated SNPs.

• 出版日期2017-11-22
• 单位上海交通大学